Incyte Corporation (INCY)vsRegeneron Pharmaceuticals Inc (REGN)
INCY
Incyte Corporation
$92.23
+1.78%
HEALTHCARE · Cap: $18.03B
REGN
Regeneron Pharmaceuticals Inc
$749.47
+1.05%
HEALTHCARE · Cap: $78.41B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 179% more annual revenue ($14.34B vs $5.14B). REGN leads profitability with a 31.4% profit margin vs 25.0%. INCY appears more attractively valued with a PEG of 0.32. INCY earns a higher WallStSmart Score of 83/100 (A-).
INCY
Exceptional Buy83
out of 100
Grade: A-
REGN
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+67.0%
Fair Value
$299.99
Current Price
$92.23
$207.76 discount
Margin of Safety
-165.8%
Fair Value
$281.93
Current Price
$749.47
$467.54 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Safe zone — low bankruptcy risk
Every $100 of equity generates 30 in profit
Keeps 25 of every $100 in revenue as profit
Attractively priced relative to earnings
Strong operational efficiency at 25.6%
Keeps 31 of every $100 in revenue as profit
Safe zone — low bankruptcy risk
Large-cap with strong market position
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 23.1%
Areas to Watch
No major concerns identified
Expensive relative to growth rate
2.5% revenue growth
Weak financial health signals
Earnings declined 2.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : INCY
The strongest argument for INCY centers on PEG Ratio, Altman Z-Score, Return on Equity. Profitability is solid with margins at 25.0% and operating margin at 25.6%. Revenue growth of 27.8% demonstrates continued momentum.
Bull Case : REGN
The strongest argument for REGN centers on Profit Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 31.4% and operating margin at 23.1%.
Bear Case : INCY
No major red flags identified for INCY, but monitor valuation.
Bear Case : REGN
The primary concerns for REGN are PEG Ratio, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
INCY profiles as a growth stock while REGN is a value play — different risk/reward profiles.
INCY carries more volatility with a beta of 0.84 — expect wider price swings.
INCY is growing revenue faster at 27.8% — sustainability is the question.
REGN generates stronger free cash flow (922M), providing more financial flexibility.
Bottom Line
INCY scores higher overall (83/100 vs 58/100), backed by strong 25.0% margins and 27.8% revenue growth. Both earn "Exceptional Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Incyte Corporation
HEALTHCARE · BIOTECHNOLOGY · USA
Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?